RxDoctor Payments Data

Guilherme Oliveira, MD

Cardiovascular Disease · Tampa, FLNPI 1699879098

Payments from drug & device makers

$81,047in general payments, 2019–2025

Across 124 payments — averaging $653.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$26K
  • Pfizer$23K
  • Novartis$12K
  • Abbott$7K
  • Alnylam Pharmaceuticals Inc.$6K
  • E.r. Squibb & Sons, L.L.C.$3K
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$17,81123%
  • Speaking & faculty fees$48,63562%
  • Travel & lodging$8,13410%
  • Food & beverage$4,4726%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,047 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$58,901
Medicare patients
268
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$458,506
EntrestoSacubitril/Valsartan327$421,705
FarxigaDapagliflozin Propanediol326$390,979
VyndaqelTafamidis Meglumine16$335,542
Repatha SureclickEvolocumab106$137,366
EliquisApixaban89$122,798
MounjaroTirzepatide76$92,995
OzempicSemaglutide66$89,853
Repatha PushtronexEvolocumab70$51,538
JardianceEmpagliflozin25$40,724
CorlanorIvabradine Hcl30$25,245
Praluent PenAlirocumab33$24,356
KerendiaFinerenone20$22,005
XareltoRivaroxaban24$20,833
WegovySemaglutide16$20,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$23,358$916,846127 claims
NovartisEntresto$12,325$421,705327 claims
Novo NordiskOzempic, Wegovy$26$110,60282 claims
AmgenCorlanor$257$25,24530 claims
Johnson & JohnsonXarelto$32$20,83324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →